Toltrazuril in Veterinary Research: A Review of Parasitological Studies (Educational Overview)
Coccidiosis and Equine Protozoal Myeloencephalitis (EPM) are complex protozoal conditions studied in multiple animal species, from poultry and livestock to horses.
This article provides an educational summary of how toltrazuril has been examined in veterinary research, with citations from peer-reviewed literature and expert sources.
Our intent is to clarify what current studies show about toltrazuril’s pharmacology, species-specific research, and relevance under veterinary oversight—not to promote use or imply approval.
What is Toltrazuril?
Toltrazuril is a synthetic triazine-class compound that has been studied for activity against protozoal parasites such as Eimeria, Isospora, and Sarcocystis.
Originally evaluated in poultry and livestock research, toltrazuril has also been explored in connection with equine protozoal diseases like EPM (Sarcocystis neurona).
All information presented here derives from published scientific literature and veterinary manuals (e.g., Merck Veterinary Manual, PubMed studies) and is educational only.
Toltrazuril is not approved by the U.S. FDA for treating or preventing any disease in animals.
INVESTIGATED MECHANISM OF ACTION (EDUCATIONAL)
Toltrazuril belongs to the triazine class of compounds. It has been studied for its mechanism of action, which research suggests involves interfering with nuclear division and energy metabolism in protozoa. Light and electron microscopy studies have observed that toltrazuril may damage multiple intracellular stages. By disrupting parasite development, researchers have investigated its potential to reduce the shedding of infectious spores. It is administered orally and is absorbed systemically. Notably, toltrazuril’s active metabolite is ponazuril (toltrazuril sulfone), which has a long half-life. This long persistence has been a focus of research.
TOLTRAZURIL IN POULTRY: A REVIEW OF COCCIDIOSIS RESEARCH
Coccidiosis in poultry (caused by Eimeria protozoa) is one of the most common and costly subjects of health management research in chickens, turkeys, and other birds. Infected birds may develop diarrhea, intestinal lesions, poor feed conversion, weight loss, and mortality. Toltrazuril 5% solution has been the subject of veterinary research focused on managing coccidial challenges in poultry.
Parasite Life Cycle and Lesions
In one controlled broiler chicken trial, researchers studied toltrazuril's effect on intestinal lesions and oocyst shedding in feces compared to untreated birds. The study observed and reported a reduction in clinical signs and environmental contamination in the treated flock. By halting oocyst output, the study investigated toltrazuril's role in breaking the cycle of reinfection.
Growth and Feed Conversion
Because coccidiosis can damage the gut lining and hinder nutrient absorption, affected poultry often suffer stunted growth. Research has examined whether interventions could support normal growth. In some studies, flocks in environments with coccidiosis challenges showed weight gains and feed conversion ratios on par with uninfected healthy birds, whereas untreated, infected birds lagged behind.
Flock-Wide Administration
A key topic in poultry research is the method of administration. Studies have confirmed that toltrazuril can be administered in drinking water, which is a practical method for large-scale operations. This research is crucial for practical application in field settings.
Toltrazuril’s success in poultry is reflected in its broad adoption as a component of coccidiosis management programs. It is often used therapeutically to treat active outbreaks and metaphylactically to halt subclinical infections before they escalate. Importantly, toltrazuril is effective even against Eimeria strains that may have resistance to older coccidiostats, because it acts on multiple parasite stages and has a unique mode of action. To maintain efficacy, experts recommend using toltrazuril as part of an integrated program – including good hygiene (dry, clean litter), biosecurity to reduce spread, and possibly rotating anticoccidial drugs or vaccines over time. Always consult a poultry veterinarian for proper diagnosis, dosing instructions, and observance of any withdrawal periods for meat/eggs after treatment.
While toltrazuril is discussed as a model anticoccidial in research, its use in U.S. poultry operations is not FDA-approved, and any product application must occur under veterinary prescription and local law.
Toltrazuril in Livestock: Pigs, Cattle, Sheep & Goats
Prohibition in U.S. Food Animals: Because toltrazuril is unapproved in the U.S. and lacks established maximum residue limits (MRLs) for human food products, its use in any form in food-producing animals in the United States is illegal. This is a critical public health protection. Beyond poultry, toltrazuril has become a commonly discussed topic in research for coccidiosis in many livestock species. Young farm animals are highly susceptible to coccidial parasites which cause diarrhea, poor growth, and death. In research, toltrazuril’s one-time dosing and persistence have made it a subject of study for these issues.
Toltrazuril’s success in poultry research is reflected in its broad discussion as a component of coccidiosis research programs. It is often studied therapeutically in active outbreaks and metaphylactically for subclinical infections. To maintain research efficacy, experts recommend discussing toltrazuril as part of an integrated program – including good hygiene, biosecurity, and rotating anticoccidial drugs. Always consult a poultry veterinarian for proper dosing and observance of withdrawal periods. While toltrazuril is discussed as a model anticoccidial in research, its use in U.S. poultry operations is not FDA-approved, and any product application must occur under veterinary prescription and local law.
Piglets (Neonatal porcine coccidiosis)
Isospora suis is a common protozoan parasite affecting piglets in early life, often linked to gastrointestinal disturbance and reduced growth rates. In countries where toltrazuril is approved, researchers have investigated its effects on piglet health under veterinary supervision. Peer-reviewed studies have reported reduced parasite shedding, improved digestive stability, and stronger growth performance in litters managed with toltrazuril as part of comprehensive neonatal care protocols. These findings are based on controlled trials conducted in commercial farm settings outside the U.S. Toltrazuril is not approved by the U.S. Food and Drug Administration (FDA) for use in swine. Any use in the U.S. must occur under the direction of a licensed veterinarian and in compliance with applicable regulations, including withdrawal periods for meat-producing animals. This summary is intended for informational and veterinary reference purposes only.
Calves and Lambs
Calves and lambs are vulnerable to species-specific coccidial infections during early development, particularly under intensive or high-density management systems. In veterinary research conducted in regions where toltrazuril is approved, studies have documented reductions in parasite burden and improvements in performance metrics such as weight gain and feed efficiency when toltrazuril was incorporated into herd-level management protocols. Reported outcomes have included decreased oocyst shedding and milder clinical signs in treated groups compared to controls. These studies were conducted under veterinary supervision and in accordance with local regulations. Toltrazuril is not FDA-approved for use in calves or lambs in the United States and may only be used under the oversight of a licensed veterinarian. This content is for educational and research discussion purposes only.
Other Livestock
Toltrazuril has been studied in a range of species beyond swine, calves, and lambs — including goat kids, rabbits, camelids, and game birds — in regions where its use is approved. Veterinary literature has explored its role in managing protozoal infections such as coccidiosis, often in conjunction with improved husbandry practices. These studies report species-specific outcomes and emphasize that use must follow strict veterinary protocols and legal requirements. In the United States, toltrazuril is not approved for use in any animal species by the FDA. Any consideration of use must be made under veterinary supervision and in compliance with federal and local laws. This article is intended as a summary of published veterinary literature and does not constitute medical advice or endorsement of use.
Use in Companion Animals: Puppies & Kittens (Educational Review)
Pet owners and breeders may encounter coccidiosis in puppies and kittens, where Cystoisospora parasites can cause diarrhea. While there are approved treatments in the US (such as sulfadimethoxine), toltrazuril has also been a subject of study. In Europe, a veterinary oral suspension combining emodepside + toltrazuril is licensed (product name Procox®). A recent study from Spain (2024) demonstrated an outcome in a kennel setting: at a facility with recurring puppy diarrhea, a single metaphylactic toltrazuril dose given to all 35-day-old pups resulted in no treated puppies developing clinical coccidiosis, and oocyst shedding was reported as eliminated in the group. This highlights the focus of toltrazuril research in breaking transmission. Likewise, field observations by veterinarians have been published regarding Cystoisospora diarrhea in puppies. For kittens, research data in felines are scarcer. Ponazuril (the metabolite) is another option that’s been extrapolated from equine use. It’s critical to emphasize that toltrazuril is not officially approved for pets in the U.S., so any use in dogs or cats is extra-label and must be under veterinary guidance. Pet breeders should consult their vet for appropriate protocols. Administering this compound without professional input is strongly discouraged. Good sanitation and prompt fecal testing are key to managing coccidia in kennels.
Toltrazuril and EPM in Horses (Educational Review)
One reason toltrazuril garners interest is its discussion in research related to Equine Protozoal Myeloencephalitis (EPM), a serious neurologic disease in horses. EPM is caused by protozoa (Sarcocystis neurona) that infect the horse’s central nervous system. The standard EPM therapies are ponazuril (Marquis®), diclazuril (Protazil®), or a sulfadiazine+pyrimethamine combination – all FDA-approved drugs. Toltrazuril is the parent compound of ponazuril. Although toltrazuril is not FDA-approved for horses, some veterinarians have explored it as an off-label alternative, particularly in complex cases. Early research has investigated whether toltrazuril can penetrate the central nervous system. Its long half-life has also been a subject of study. One clinical trial in the early 2000s evaluated toltrazuril sulfone (ponazuril) and found that treated horses were significantly more likely to improve neurologically than untreated. Another small study on toltrazuril observed that even at very high doses, horses only had mild side effects, though this study was limited. That said, formal efficacy trials of toltrazuril in EPM are limited. Most EPM experts continue to rely on ponazuril or diclazuril as first-line treatments. The interest in toltrazuril arises from its pharmacologic properties and anecdotal reports. Crucially, any use of toltrazuril for EPM must be done under strict veterinary supervision. The veterinarian can prescribe a suitable compounded formulation. Because EPM is a variable disease, horses should be re-evaluated during any protocol. In summary, toltrazuril is a topic of interest in EPM research due to its chemical properties. It represents an area of ongoing investigation. However, owners must work closely with their vet and understand that toltrazuril for EPM is off-label, and regulatory restrictions may apply.
Safety, Resistance, and Best Practices (Educational)
When used according to veterinary direction, toltrazuril’s safety profile has been a subject of study. Research investigating toxicity has been published – even at doses several times higher than recommended, animals in these studies generally showed only mild, transient effects. That said, any medication can cause adverse reactions. Producers and pet owners should observe animals during any protocol. Another consideration is drug resistance: excessive or frequent use of toltrazuril could contribute to parasites developing resistance. To mitigate this, veterinarians may recommend integrating toltrazuril with other control measures (hygiene, etc.). From a regulatory standpoint, consulting a veterinarian before purchasing or using toltrazuril is essential. A veterinarian will provide context based on species and weight and ensure that any protocol is appropriate for the particular case. They will also inform you of any required withdrawal times. In the United States, toltrazuril products sold online for animals are unapproved. The Food & Drug Administration (FDA) has issued warnings about some online sales. This means its sale and use must be overseen by veterinarians to protect animal welfare and public health.
Conclusion
Toltrazuril continues to be a topic of active veterinary research across species ranging from poultry to equines.
Findings highlight its mechanistic activity against protozoal life stages and potential applications under veterinary prescription.
However, toltrazuril is not FDA-approved for disease use in animals within the U.S., and all practical decisions regarding use, sourcing, and compliance must be made under professional veterinary direction.
Educational awareness and science-based management are key to ensuring responsible use of all anticoccidial compounds.
References: Real-world research and authoritative sources were used in compiling this article. Key references include the Merck Veterinary Manual for coccidiosis in various species, controlled studies from Veterinary Parasitology and Parasites & Vectors journals demonstrating toltrazuril’s efficacy in poultry and livestock, a 2024 kennel study on puppies published in Vet Parasitol Regional Reports, an FDA advisory on toltrazuril use in animals, and veterinary clinical insights on EPM treatments including toltrazuril. These and other cited sources provide a fact-based foundation for the information presented. Always refer to veterinary professionals and up-to-date guidance when making animal health decisions.